Reduced Androgen Receptor Expression Accelerates the Onset of ERBB2 Induced Breast Tumors in Female Mice

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Hodgson, Myles C ^a   VanOstran, Garrett ^a   Alghamdi, Sarah ^b   Poppiti, Robert J ^b   Agoulnik, Alexander I ^a,c   Agoulnik, Irina U ^a,c  

^a FLORIDA INTERNATIONAL UNIVERSITY   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; ESTROGEN RECEPTOR ALPHA; HEPATOCYTE NUCLEAR FACTOR 3ALPHA; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOGENESIS; BREAST EPITHELIUM; BREAST TUMOR; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HETEROZYGOTE; MALE; MALIGNANT TRANSFORMATION; MAMMARY GLAND; MOSAICISM; MOUSE; NONHUMAN; ONCOGENE ERBB2;

ALLELES; ANIMALS; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKOUT TECHNIQUES; HUMANS; MALE; MAMMARY GLANDS, ANIMAL; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, TRANSGENIC; ONCOGENES; ORGAN SPECIFICITY; RATS; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; RECEPTORS, ANDROGEN; RECEPTORS, PROGESTERONE; SIGNAL TRANSDUCTION;

MOUSE MAMMARY TUMOR VIRUS; MUS;

EID: 84875991829     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0060455     Document Type: Article

References (53)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, et al. (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182.
2. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, et al. (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712.
3. Moasser MM, (2007) The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 26: 6469-6487.
4. Lee-Hoeflich ST, Crocker L, Yao E, Pham T, Munroe X, et al. (2008) A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res 68: 5878-5887.
5. Bouchard L, Lamarre L, Tremblay PJ, Jolicoeur P, (1989) Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/c-neu oncogene. Cell 57: 931-936.
6. Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, et al. (1992) Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci U S A 89: 10578-10582.
7. Muller WJ, Sinn E, Pattengale PK, Wallace R, Leder P, (1988) Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 54: 105-115.
8. Vaught DB, Stanford JC, Young C, Hicks DJ, Wheeler F, et al. (2012) HER3 is required for HER2-induced preneoplastic changes to the breast epithelium and tumor formation. Cancer Res 72: 2672-2682.
9. Jackson-Fisher AJ, Bellinger G, Shum E, Duong JK, Perkins AS, et al. (2006) Formation of Neu/ErbB2-induced mammary tumors is unaffected by loss of ErbB4. Oncogene 25: 5664-5672.
10. Siegel PM, Ryan ED, Cardiff RD, Muller WJ, (1999) Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer. EMBO J 18: 2149-2164.
11. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365: 1687-1717.
12. Bonneterre J, Buzdar A, Nabholtz JM, Robertson JF, Thurlimann B, et al. (2001) Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 92: 2247-2258.
13. Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, et al. (2003) Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 21: 2101-2109.
14. Paridaens RJ, Dirix LY, Beex LV, Nooij M, Cameron DA, et al. (2008) Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. J Clin Oncol 26: 4883-4890.
15. Lydon JP, DeMayo FJ, Conneely OM, O'Malley BW, (1996) Reproductive phenotpes of the progesterone receptor null mutant mouse. J Steroid Biochem Mol Biol 56: 67-77.
16. Korach KS, Couse JF, Curtis SW, Washburn TF, Lindzey J, et al. (1996) Estrogen receptor gene disruption: molecular characterization and experimental and clinical phenotypes. Recent Prog Horm Res 51: 159-186; discussion 186-158.
17. Lydon JP, Ge G, Kittrell FS, Medina D, O'Malley BW, (1999) Murine mammary gland carcinogenesis is critically dependent on progesterone receptor function. Cancer Res 59: 4276-4284.
18. Day JK, Besch-Williford C, McMann TR, Hufford MG, Lubahn DB, et al. (2001) Dietary genistein increased DMBA-induced mammary adenocarcinoma in wild-type, but not ER alpha KO, mice. Nutr Cancer 39: 226-232.
19. Gonzalez LO, Corte MD, Vazquez J, Junquera S, Sanchez R, et al. (2008) Androgen receptor expresion in breast cancer: relationship with clinicopathological characteristics of the tumors, prognosis, and expression of metalloproteases and their inhibitors. BMC Cancer 8: 149.
20. Peters AA, Buchanan G, Ricciardelli C, Bianco-Miotto T, Centenera MM, et al. (2009) Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer. Cancer Res 69: 6131-6140.
21. Hu R, Dawood S, Holmes MD, Collins LC, Schnitt SJ, et al. (2011) Androgen receptor expression and breast cancer survival in postmenopausal women. Clin Cancer Res 17: 1867-1874.
22. Ni M, Chen Y, Lim E, Wimberly H, Bailey ST, et al. (2011) Targeting androgen receptor in estrogen receptor-negative breast cancer. Cancer Cell 20: 119-131.
23. Farmer P, Bonnefoi H, Becette V, Tubiana-Hulin M, Fumoleau P, et al. (2005) Identification of molecular apocrine breast tumours by microarray analysis. Oncogene 24: 4660-4671.
24. Teschendorff AE, Naderi A, Barbosa-Morais NL, Caldas C, (2006) PACK: Profile Analysis using Clustering and Kurtosis to find molecular classifiers in cancer. Bioinformatics 22: 2269-2275.
25. Peters AA, Ingman WV, Tilley WD, Butler LM, (2011) Differential effects of exogenous androgen and an androgen receptor antagonist in the peri- and postpubertal murine mammary gland. Endocrinology 152: 3728-3737.
26. Simanainen U, Gao YR, Walters KA, Watson G, Desai R, et al. (2012) Androgen resistance in female mice increases susceptibility to DMBA-induced mammary tumors. Horm Cancer 3: 113-124.
27. Bieche I, Onody P, Tozlu S, Driouch K, Vidaud M, et al. (2003) Prognostic value of ERBB family mRNA expression in breast carcinomas. Int J Cancer 106: 758-765.
28. Srinivasan R, Poulsom R, Hurst HC, Gullick WJ, (1998) Expression of the c-erbB-4/HER4 protein and mRNA in normal human fetal and adult tissues and in a survey of nine solid tumour types. J Pathol 185: 236-245.
29. Wagner KU, Wall RJ, St-Onge L, Gruss P, Wynshaw-Boris A, et al. (1997) Cre-mediated gene deletion in the mammary gland. Nucleic Acids Res 25: 4323-4330.
30. De Gendt K, Swinnen JV, Saunders PT, Schoonjans L, Dewerchin M, et al. (2004) A Sertoli cell-selective knockout of the androgen receptor causes spermatogenic arrest in meiosis. Proc Natl Acad Sci U S A 101: 1327-1332.
31. Notini AJ, Davey RA, McManus JF, Bate KL, Zajac JD, (2005) Genomic actions of the androgen receptor are required for normal male sexual differentiation in a mouse model. J Mol Endocrinol 35: 547-555.
32. Yeh S, Tsai MY, Xu Q, Mu XM, Lardy H, et al. (2002) Generation and characterization of androgen receptor knockout (ARKO) mice: an in vivo model for the study of androgen functions in selective tissues. Proc Natl Acad Sci U S A 99: 13498-13503.
33. Pietras RJ, Arboleda J, Reese DM, Wongvipat N, Pegram MD, et al. (1995) HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 10: 2435-2446.
34. Toneff MJ, Du Z, Dong J, Huang J, Sinai P, et al. (2010) Somatic expression of PyMT or activated ErbB2 induces estrogen-independent mammary tumorigenesis. Neoplasia 12: 718-726.
35. Augello MA, Hickey TE, Knudsen KE, (2011) FOXA1: master of steroid receptor function in cancer. EMBO J 30: 3885-3894.
36. Jozwik KM, Carroll JS (2012) Pioneer factors in hormone-dependent cancers. Nat Rev Cancer.
37. Mehta RJ, Jain RK, Leung S, Choo J, Nielsen T, et al. (2012) FOXA1 is an independent prognostic marker for ER-positive breast cancer. Breast Cancer Res Treat 131: 881-890.
38. Naderi A, Meyer M, Dowhan DH, (2012) Cross-regulation between FOXA1 and ErbB2 signaling in estrogen receptor-negative breast cancer. Neoplasia 14: 283-296.
39. Drinkwater NR, Ginsler JJ, (1986) Genetic control of hepatocarcinogenesis in C57BL/6J and C3H/HeJ inbred mice. Carcinogenesis 7: 1701-1707.
40. Festing MF, Lin L, Devereux TR, Gao F, Yang A, et al. (1998) At least four loci and gender are associated with susceptibility to the chemical induction of lung adenomas in A/J x BALB/c mice. Genomics 53: 129-136.
41. Rowse GJ, Ritland SR, Gendler SJ, (1998) Genetic modulation of neu proto-oncogene-induced mammary tumorigenesis. Cancer Res 58: 2675-2679.
42. Rose DP, (1988) Endocrine epidemiology of male breast cancer (review). Anticancer Res 8: 845-850.
43. Geschickter CF, (1939) Mammary Carcinoma in the Rat with Metastasis Induced by Estrogen. Science 89: 35-37.
44. Hewitt SC, Bocchinfuso WP, Zhai J, Harrell C, Koonce L, et al. (2002) Lack of ductal development in the absence of functional estrogen receptor alpha delays mammary tumor formation induced by transgenic expression of ErbB2/neu. Cancer Res 62: 2798-2805.
45. Hickey TE, Robinson JL, Carroll JS, Tilley WD (2012) Minireview: The Androgen Receptor in Breast Tissues: Growth Inhibitor, Tumor Suppressor, Mol Endocrinol.
46. Taneja P, Frazier DP, Kendig RD, Maglic D, Sugiyama T, et al. (2009) MMTV mouse models and the diagnostic values of MMTV-like sequences in human breast cancer. Expert Rev Mol Diagn 9: 423-440.
47. Toneff MJ, Du Z, Dong J, Huang J, Sinai P,et al. Somatic expression of PyMT or activated ErbB2 induces estrogen-independent mammary tumorigenesis. Neoplasia 12: 718-726.
48. Vargo-Gogola T, Rosen JM, (2007) Modelling breast cancer: one size does not fit all. Nat Rev Cancer 7: 659-672.
49. Bernardo GM, Keri RA, (2012) FOXA1: a transcription factor with parallel functions in development and cancer. Biosci Rep 32: 113-130.
50. Gao N, Ishii K, Mirosevich J, Kuwajima S, Oppenheimer SR, et al. (2005) Forkhead box A1 regulates prostate ductal morphogenesis and promotes epithelial cell maturation. Development 132: 3431-3443.
51. Mehta RJ, Jain RK, Leung S, Choo J, Nielsen T, et al. (2012) FOXA1 is an independent prognostic marker for ER-positive breast cancer. Breast Cancer Res Treat 131: 881-890.
52. Naderi A, Meyer M, Dowhan DH, (2012) Cross-regulation between FOXA1 and ErbB2 signaling in estrogen receptor-negative breast cancer. Neoplasia 14: 283-296.
53. Naderi A, Hughes-Davies L, (2008) A functionally significant cross-talk between androgen receptor and ErbB2 pathways in estrogen receptor negative breast cancer. Neoplasia 10: 542-548.